(P123) Reducing Time From Patient CT Simulation (CT SIM) Appointment Time to Start of Actual CT Scan: Lean Thinking in the VA System

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

By applying Lean thinking, we were able to reduce the time for CT image acquisition for prostate cancer patients requiring radiotherapy planning by 22%. By reducing the time for CT SIM, veterans’ experiences and satisfaction were improved, flow through the radiation oncology department was optimized, and capacity for CT SIMs was increased.

Alice V. Cheuk, MD, George A. Dawson, MD, Jorge H. Restrepo, AS; James J. Peters VA Medical Center

PURPOSE: Computed tomography simulation (CT SIM) is vital to planning a patient’s radiation treatment (RT) and often takes a considerable amount of time to perform. This is particularly true of prostate patients, who have to drink until their bladders are full for the scan. CT SIM appointments are scheduled for 60 minutes, but preliminary observations have found that images are often acquired after the hour mark. The goal of the study was to reduce the time from CT SIM appointment/registration time to actual CT image acquisition for prostate CT SIMs, using Lean methodology.

METHODS: Observation of the process was performed (Gemba walking) to map out the current process and to document time from appointment/registration to actual CT image acquisition. Each step in the process was diagrammed, timed, and recorded. The current map underwent workflow analysis, and areas of delay/redundancy were modified or eliminated. A new process map was generated and put into practice. Five CT SIMs were timed and recorded as before. A sustain plan was implemented, involving measures to maintain use of the new map, and CT SIMs were timed to ensure continuation of the new process.

RESULTS: A total of 10 CT SIMs were timed with the old process, and the average time was 46.6 minutes. On analysis, the old process map had 16 steps with major barriers, which included time needed to consume water before CT SIM, time for consent, and delays caused by patients needing to urinate before the scan, requiring the process to be restarted from the beginning. Several steps were eliminated/consolidated, including waiting for the consent to be completed before starting the drinking process (consolidated), having the front desk call therapists to notify them that the patient is ready (eliminated), and having therapists tell the patient to start drinking (eliminated). After these changes were made, there were 10 steps in the new process map, and the average time for CT acquisition was shortened to 36.2 minutes, a 22% improvement. These changes were maintained with the sustain plan, as revealed by an acquisition time of 32 minutes during the sustain phase.

CONCLUSIONS: By applying Lean thinking, we were able to reduce the time for CT image acquisition for prostate cancer patients requiring radiotherapy planning by 22%. By reducing the time for CT SIM, veterans’ experiences and satisfaction were improved, flow through the radiation oncology department was optimized, and capacity for CT SIMs was increased.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Related Content